ANI PHARMACEUTICALS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 62.57 USD | -1.88% |
|
-7.29% | +14.42% |
| May. 16 | Ani Pharmaceuticals Insider Sold Shares Worth $1,101,821, According to a Recent SEC Filing | MT |
| May. 10 | ANI Pharmaceuticals Seeks M&A | CI |
Presenter SpeechPatrick Walsh (Executives)Good morning. I'm Patrick Walsh, Chairman of the Boa...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company, which serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Its three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products. The Company has a commercial portfolio of 116 products with a variety of indications and a robust portfolio of pipeline products. It has acquired the NDAs for and market Atacand, Atacand HCT, Arimidex, Casodex, Lithobid, Vancocin, Inderal LA, Inderal XL, InnoPran XL, Oxistat, Veregen, and Pandel. The Company sources the raw materials for its products from both domestic and international suppliers.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
63.77
USD
Average target price
80.2
USD
Spread / Average Target
+25.76%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +14.42% | 1.24B | |
| +32.34% | 694B | |
| +29.39% | 593B | |
| -1.60% | 371B | |
| +19.90% | 331B | |
| +6.59% | 290B | |
| +14.08% | 239B | |
| -3.07% | 209B | |
| +9.92% | 209B | |
| +8.02% | 169B |
- Stock Market
- Equities
- ANIP Stock
- News ANI Pharmaceuticals, Inc.
- Transcript : ANI Pharmaceuticals, Inc. - Shareholder/Analyst Call